Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Int J Cancer
    May 2025
  1. PATEL DP, Loffredo CA, Pupacdi B, Rabibhadana S, et al
    Associations of chronic liver disease and liver cancer with glyphosate and its metabolites in Thailand.
    Int J Cancer. 2025;156:1885-1897.
    >> Share

    March 2025
  2. AGLAGO EK, Ramos I, Keski-Rahkonen P, Chatziioannou C, et al
    Alcohol and smoking habits in association with hepatocellular carcinoma risk.
    Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35401.
    >> Share

  3. GAO Y, Cheng AL, Li LX, Parent N, et al
    Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35407.
    >> Share

  4. JIANG X, Zhang Q, Zheng Z, Shen Z, et al
    Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.
    Int J Cancer. 2025 Mar 12. doi: 10.1002/ijc.35399.
    >> Share

  5. CHIVITE-LACABA M, Justo I, Utrero-Rico A, Caso O, et al
    Delineation of monocytic and early-stage myeloid-derived suppressor cells in the peripheral blood of patients with hepatocarcinoma.
    Int J Cancer. 2025 Mar 7. doi: 10.1002/ijc.35390.
    >> Share

    January 2025
  6. HE M, Xie W, Yuan Z, Chen J, et al
    Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study.
    Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35341.
    >> Share

    December 2024
  7. HUANG M, Song C, Zhou X, Wang H, et al
    Tissue-matched analysis of MRI evaluating the tumor infiltrating lymphocytes in hepatocellular carcinoma.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35281.
    >> Share

  8. REMOND M, Smolenschi C, Tarabay A, Gelli M, et al
    Clinical and molecular features of early onset pancreatic adenocarcinoma.
    Int J Cancer. 2024;155:1969-1981.
    >> Share

    November 2024
  9. TRAILIN A, Ali E, Ye W, Pavlov S, et al
    Prognostic assessment of T-cells in primary colorectal cancer and paired synchronous or metachronous liver metastasis.
    Int J Cancer. 2024 Nov 7. doi: 10.1002/ijc.35252.
    >> Share

  10. WATLING CZ, Kelly RK, Watts EL, Graubard BI, et al
    Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35244.
    >> Share

    October 2024
  11. LIU J, Zhang X, Lin J, Dai C, et al
    HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy.
    Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35224.
    >> Share

    September 2024
  12. HO NT, Abe SK, Rahman MS, Islam R, et al
    Diabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium.
    Int J Cancer. 2024;155:854-870.
    >> Share

    August 2024
  13. HUANG H, Zhao Y, Deng Y, Zhan Z, et al
    Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study.
    Int J Cancer. 2024 Aug 26. doi: 10.1002/ijc.35139.
    >> Share

  14. BUI TT, Park E, Kang HY, Oh JK, et al
    Combined effects of smoking and alcohol consumption on the risk of liver cancer according to metabolic syndrome: A nested case-control study in South Korea.
    Int J Cancer. 2024;155:654-665.
    >> Share

    July 2024
  15. VAZ J, Jepsen P, Stromberg U, Midlov P, et al
    Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35097.
    >> Share

    June 2024
  16. ZHAO L, Zhang X, Birmann BM, Danford CJ, et al
    Pre-diagnostic plasma inflammatory proteins and risk of hepatocellular carcinoma in three population-based cohort studies from the United States and the United Kingdom.
    Int J Cancer. 2024 Jun 11. doi: 10.1002/ijc.35054.
    >> Share

  17. KARA-ALI GH, Cano L, Dion S, Imerzoukene G, et al
    Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
    Int J Cancer. 2024;154:1999-2013.
    >> Share

    May 2024
  18. PUPACDI B, Loffredo CA, Budhu A, Rabibhadana S, et al
    The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand.
    Int J Cancer. 2024 May 18. doi: 10.1002/ijc.35034.
    >> Share

  19. GERBER TS, Ridder DA, Goeppert B, Brobeil A, et al
    N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
    Int J Cancer. 2024;154:1857-1868.
    >> Share

    February 2024
  20. QIN XY, Shirakami Y, Honda M, Yeh SH, et al
    Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
    Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893.
    >> Share

  21. YU Z, Bai X, Zhou R, Ruan G, et al
    Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019.
    Int J Cancer. 2024;154:615-625.
    >> Share

  22. XU FQ, Xu QY, Zhu ZJ, Jin L, et al
    Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study.
    Int J Cancer. 2024;154:530-537.
    >> Share

  23. JIANG L, Zhao N, Xu M, Pei J, et al
    Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: An age-period-cohort analysis.
    Int J Cancer. 2024;154:465-476.
    >> Share

  24. BARUPAL DK, Ramos ML, Florio AA, Wheeler WA, et al
    Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.
    Int J Cancer. 2024;154:454-464.
    >> Share

    January 2024
  25. ZHAO G, Shi X, Zhang L, Liang H, et al
    Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34796.
    >> Share

  26. KIM MN, Zhang X, Ahn SH
    Reply to: Comments on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34797.
    >> Share

    November 2023
  27. ROSSARI F, Tada T, Suda G, Shimose S, et al
    alpha-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Int J Cancer. 2023 Nov 23. doi: 10.1002/ijc.34799.
    >> Share

    October 2023
  28. SOMMERHAUSER G, Karthaus M, Kurreck A, Ballhausen A, et al
    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34760.
    >> Share

  29. SIRIRUNGREUNG A, Lee PC, Hu YH, Liew Z, et al
    Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population-based cohort study in Taiwan, 2004 to 2015.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34744.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016